文献速递鼻科

鼻内抗胆碱能药物治疗慢性鼻炎:系统综述与荟萃分析

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta-Analysis.
PubMed 文献 · Laryngoscope · 2022-07-15

该系统综述与荟萃分析检索Cochrane Library、PubMed/MEDLINE和Scopus,纳入12项研究(n=2024)进行定性合成,9项(n=1920)进行荟萃分析。与安慰剂相比,抗胆碱能鼻喷剂可显著降低过敏性和非过敏性鼻炎患者的鼻漏严重度评分和持续时间,仅鼻出血风险显著高于安慰剂。

要点

  • 抗胆碱能鼻喷剂可显著降低过敏性和非过敏性鼻炎患者的鼻漏严重度评分和持续时间。
  • 对鼻塞、后鼻滴漏和打喷嚏的获益较不一致。
  • 与安慰剂相比,仅鼻出血风险显著增加(RR 2.19,95%CI 1.22-3.93)。

核心结论

  • 抗胆碱能鼻喷剂在减少两种鼻炎病因的鼻漏严重度和持续时间方面似乎安全有效,尽管对其他症状的获益较少。
  • 该证据支持其继续用于治疗鼻炎相关鼻漏。

研究设计与样本

  • 系统综述与荟萃分析,检索Cochrane Library、PubMed/MEDLINE和Scopus数据库。
  • 检索获得1029篇独特摘要,12项研究(n=2024)符合纳入标准进入定性合成,9项(n=1920)进入荟萃分析。
  • 中位随访时间为4周,异丙托溴铵是试验最多的抗胆碱能药物。

主要发现

  • 与安慰剂相比,抗胆碱能治疗显著降低过敏性鼻炎患者的鼻漏严重度评分(标准化均数差[95%CI]=-0.77[-1.20,-0.35])和持续时间(-0.62[-0.95,-0.30])。
  • 与安慰剂相比,抗胆碱能治疗显著降低非过敏性鼻炎患者的鼻漏严重度评分(标准化均数差[95%CI]=-0.43[-0.72,-0.13])和持续时间(-0.29[-0.47,-0.10])。
  • 对鼻塞、后鼻滴漏和打喷嚏症状的获益较不一致。
  • 报告的不良反应包括鼻黏膜干燥或刺激、鼻出血、头痛和咽炎,但与安慰剂比较仅鼻出血风险显著更高(风险比[95%CI]=2.19[1.22,3.93])。

临床怎么用

  • 原文结论指出,抗胆碱能鼻喷剂在减少两种鼻炎病因的鼻漏严重度和持续时间方面似乎安全有效,该证据支持其继续用于治疗鼻炎相关鼻漏。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Topical intranasal anticholinergics are commonly prescribed for the relief of chronic rhinitis and associated symptoms, warranting thorough assessment of the supporting evidence. The present study aimed to evaluate the safety and efficacy of anticholinergic nasal sprays in the management of allergic and non-allergic rhinitis symptom severity and duration. METHODS: A search encompassing the Cochrane Library, PubMed/MEDLINE, and Scopus databases was conducted. Primary studies describing rhinorrhea, nasal congestion, and/or postnasal drip outcomes in rhinitis patients treated with an anticholinergic spray were included for review. RESULTS: The search yielded 1,029 unique abstracts, of which 12 studies (n = 2,024) met inclusion criteria for qualitative synthesis and 9 (n = 1,920) for meta-analysis. Median follow-up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic. Compared to placebo, anticholinergic treatment was demonstrated to significantly reduce rhinorrhea severity scores (standardized mean difference [95% CI] = -0.77 [-1.20, -0.35]; -0.43 [-0.72, -0.13]) and duration (-0.62 [-0.95, -0.30]; -0.29 [-0.47, -0.10]) in allergic and non-allergic rhinitis patients respectively. Benefit was less consistent for nasal congestion, postnasal drip, and sneezing symptoms. Reported adverse effects included nasal mucosa dryness or irritation, epistaxis, headaches, and pharyngitis, though comparison to placebo found significantly greater risk for epistaxis only (risk ratio [95% CI] = 2.19 [1.22, 3.93]). CONCLUSION: Albeit treating other symptoms with less benefit, anticholinergic nasal sprays appear to be safe and efficacious in reducing rhinorrhea severity and duration in both rhinitis etiologies. This evidence supports their continued use in the treatment of rhinitis-associated rhinorrhea. LEVEL OF EVIDENCE: 1 Laryngoscope, 133:722-731, 2023.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Pang JC, Vasudev M, Du AT, et al. Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta-Analysis. Laryngoscope. 2022. PMID: 35838014. doi:10.1002/lary.30306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。